Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC/ GB0009633180 /
DPH/L
|
9/22/2023 10:48:58 AM
|
Chg.
+4.00
|
Volume |
Bid10:52:56 AM |
Ask10:52:37 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
3,806.00GBX
|
+0.11%
|
7,447
Turnover(GBP): 282,968.3000 |
3,804.00Bid Size: 548 |
3,806.00Ask Size: 101 |
4.1 bill.GBP |
- |
- |
Business description
Dechra is an international specialist veterinary pharmaceuticals products business.
Management board & Supervisory board
| CEO |
| Ian Page |
| Management board |
| Paul Sandland |
| Supervisory board |
| Alison Platt, Dr. Lawson Macartney, Ian Page, Ishbel Macpherson, Julian Heslop, Lisa Bright, Paul Sandland, Tony Griffin |
Company data
| Name: |
Dechra Pharmaceuticals PLC |
| Address: |
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam,UK-Northwich, CW9 7UA |
| Phone: |
+44-1606-814-730 |
| Fax: |
+44-1606-814-731 |
| E-mail: |
corporate.enquiries@dechra.com
|
| Internet: |
www.dechra.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
6/30 |
| Free Float: |
65.52% |
| IPO date: |
- |
Investor relations
| Name: |
Ian Page |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
-
|
Company calendar
|
CW 42 | 10/19/2023
General Shareholder Meeting
|
Main Shareholders
| Freefloat |
|
65.52% |
| Fidelity Management & Research |
|
8.22% |
| BlackRock Inc |
|
6.02% |
| Standard Life Aberdeen |
|
5.76% |
| The Vanguard Group, Inc |
|
4.47% |
| Corporate Stakeholders (Netherlands) |
|
3.39% |
| Grandeur Peak Global Advisors |
|
3.35% |
| Royal London Mutual Assurance Society |
|
3.27% |